Zogenix, Inc. (ZGNX) Social Stream



Zogenix, Inc. (ZGNX): $19.27

-0.18 (-0.93%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Featured Post From StockTwits About ZGNX

$ZGNX Interesting, on what good news ppl here want to load another 5k shares? On news that analyst said their rival's drug will be better than Fintepla and can take its market share or on news that they reserved 200 mil shares max issue while they just issued 55 mil and had 100 mil limit which speaks of big dilutions ahead? What of these news is better?)
thelambofgoat, published April 7, 2021

What Else are ZGNX Traders Talking About?


Other tickers frequently mentioned alongside ZGNX is GWPH.

Other Notable StockTweets About ZGNX


$ZGNX nearly 50% efficacy against LGS seizures. Best in class. CEO, confirmed on Stifel analyst call yesterday, uptake has equal or better cadence then $GWPH Epidiolex, using Fintepla in Dravet. 80% of all Dravet patients have no drug that controls their seizures, not even Epidiolex. Fintepla is the miracle drug. KOL’s gave spoken. Expectations are the same for LGS later this year. In fact, patient uptake has increased substantially the last 2 weeks with vaccines ramping up & patients getting in front of their drs for scripts. #bullish #biotech #Stockmarketnews #stocks

Tiger77, published April 1, 2021

$ZGNX Stifel 3rd Annual CNS Conference. Farr, CEO, “all LGS studies completed and 2 year study requested by FDA showed a clear cardiovascular study on Fintepla. sNDA Q3 2021, marketing and sales begin Q1 2022 for LGS.” “Fintepla in LGS studies showed upwards of 50% efficacy.” Best in class. No drug comes even close. M. Smith, EVP & CFO, “We’re adding on avg 150 patients per quarter, but that is on upswing the last 2 weeks with vaccines rolling out and sales reps and patients getting in front of more physicians.” A $96k orphan designated drug in US & Europe per year, per patient.

Tiger77, published March 31, 2021

$ZGNX Billionaire Jim Simons Snaps Up These 2 Biotech Stocks
Michael Marcus
Mar 08, 2021

Quant trading guru Jim Simons is calling it a day, sort of.
The mathematician and cryptologist is famous in the investing community for bringing his analytical eye to the world of the stock exchange, creating both the quant trading revolution and a personal fortune now estimated at more than $22 billion. His has been a career of multifaceted success, and his innovations on Wall Street have influenced the strategies of two successive generations of traders.

Simons staked new positions in two biotech stocks. Following Simons’ stock moves is a viable strategy for investors of all strips.

The company’s solid position is bound to attract investor attention – and Jim Simons bought in to the tune of more than 245,000 shares in Q4. His stake in the company is now worth over $5 million.

Tiger77, published March 16, 2021

$ZGNX Despite their central role in human health and disease, there are no approved drugs that directly target mitochondria. MT1621 for TK2D as been granted Orphan Designation in US & Europe. Fast Track Approval by FDA & EMA(6 months or less). MT1621 NDA Q1 2022. A estimated $1m p/patient. LGS 50% efficacy for severe tonic/clonic seizures. No existing drug has efficacy above 25%. Fintepla, a $96k year drug approved by the FDA & EMA. KOL’s all agree, Fintepla, best in class for various severe epilepsies. Germany, Italy, France already over 100 patients each in Q1. 4 weeks to go in the quarter. UK, Spain, Austria, Switzerland, and the Nordic countries are all receiving it Q1 2021. Dravet Syndrome has 1 FDA approved drug in the world, FIntepla. 20k US patients. 20k-40k in Europe it’s estimated by experts.

Tiger77, published March 4, 2021

Loading social stream, please wait...



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6577 seconds.